133 related articles for article (PubMed ID: 38552304)
1. Comparison of TERT and 5-Hydroxymethylcytocine immunohistochemistry in various thyroid carcinomas.
An HR; Kim WG; Lee YM; Sung TY; Song DE
Ann Diagn Pathol; 2024 Aug; 71():152290. PubMed ID: 38552304
[TBL] [Abstract][Full Text] [Related]
2. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract][Full Text] [Related]
3. Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations.
Oishi N; Vuong HG; Mochizuki K; Kondo T
Endocr Pathol; 2020 Dec; 31(4):359-366. PubMed ID: 33058026
[TBL] [Abstract][Full Text] [Related]
4. The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms.
Canberk S; Gonçalves J; Rios E; Povoa AA; Tastekin E; Sobrinho-Simões M; Uguz A; Aydin O; Ince U; Soares P; Máximo V
Endocr Pathol; 2024 Mar; 35(1):25-39. PubMed ID: 38285158
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
6.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
7. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
11. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
12. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
13. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
14. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
Wang N; Kjellin H; Sofiadis A; Fotouhi O; Juhlin CC; Bäckdahl M; Zedenius J; Xu D; Lehtiö J; Larsson C
Oncotarget; 2016 Apr; 7(16):21332-46. PubMed ID: 26870890
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
19.
Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
[TBL] [Abstract][Full Text] [Related]
20. Clinical features combined with ultrasound characteristics to predict TERT promoter mutations in papillary thyroid carcinoma: a single-center study over the past 5 years.
Hu Y; Xu S; Dong L; Pan Z; Zhang L; Zhan W
Front Endocrinol (Lausanne); 2024; 15():1322731. PubMed ID: 38562417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
